The rapid evolution and expansion of applications in targeted cell therapies and immunobiologics has seen significant interest in the use of biological therapies for treating disease, resulting in an evolving and complex patent space.
Challenges in product efficacy, administration, side effects and costs are driving ongoing research, with IP considerations spanning the preparation of cells, formulations and methods of administration.
HGFs team of 23 life sciences attorneys, who possess specific immunobiology academic accomplishments and in-house backgrounds, apply a cross-technology approach to building portfolios and data-driven strategies that layer protection and maximise exclusivity periods.
The team’s extensive insight into regulatory and approval pathways in this area adds a strong commercial focus to the development of economically viable strategies. Furthermore, the multidisciplinary specialists have significant experience in conducting due diligence across every aspect of immunobiology, from genes through to formulation and application processes.
Working with universities, large pharmaceutical firms and generic companies, HGF creates and protects patents for commercially important products, with significant experience of opposition and appeals before the European Patent Office.
The Austrian parliament has completed the legislative procedure to ratify the Protocol on the provisional application of the Agreement on a Unified Patent Court (the “Protocol”; see here). When deposited, …Read article
The University of Hong Kong is hosting a webinar on ‘IP Management: AI and 5G in healthcare’ on 9th December 2021 with HGF’s Partner Dr Chris Benson and Patent Director …Event details
A Leeds alumnus has been appointed as the next Pro-Chancellor of the University of Leeds. A lawyer by background, with a strong track record in leadership in education and social …Read article